Sintesi di studi scientifici - cannabinoidi in medicina

​

In questa sottosezione manteniamo un elenco aggiornato dei link, a nostro avviso,  più importanti  riferiti a studi scientifici sui cannabinoidi in medicina, suddivisi per gruppo di patologie (NON in ordine alfabetico).

​

​

GENERALI SU CANCRO E CANNABINOIDI / GENERAL STUDIES

​

• Cannabidiol as potential anticancer drug (PubMed)

• Cannabidiol inhibits angiogenesis by multiple mechanisms (PubMed)

• The inhibitory effects of cannabidiol on systemic malignant tumors (PubMed)

• Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1 (PubMed)

 

​

POLMONI / LUNGS

​

• Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1C (PubMed)

• COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells(PubMed)

• Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells (PubMed)

• Media ignored expert’s shocking findings that marijuana helps prevent lung cancer(O’Shaughnessy’s)

​

​

PROSTATA, COLON, INTESTINO / PROSTATE, INTESTINE

​

• Towards the use of non-psychoactive cannabinoids for prostate cancer (PubMed)

• In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines(Scirp.org)

• Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent (PubMed)

• Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer (PubMed)

• Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol (PubMed)

​

​

SENO /BREAST

​

• Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma (PubMed)

• Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy (PubMed)

• Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis (PubMed)

• Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells(PubMed)

• Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration (PubMed)

​

​

CERVELLO / BRAIN

​

• Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival (PubMed)

• Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines (PubMed)

• Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas (PubMed)

• Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism (PubMed)

• Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target (PubMed)

• Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents (PubMed)

• Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect (PubMed)

• Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme (PubMed)

• “The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model”

• “Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells”

• “Cannabinoids and gliomas.”

• “A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme”

• “Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism”

• “Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines”

• “Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas”

• “Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor”

​

​

LEUCEMIA / LEUKEMIA

​

• Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression (PubMed)

• Cannabidiol-Induced Apoptosis in Human Leukemia Cells (PubMed)

​

​

PELLE / SKIN

​

• Anticancer activity of anandamide in human cutaneous melanoma cells (PubMed)

​

​

SARCOMA

• Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpes virus-infected endothelium (PubMed)

​

​

SISTEMA ENDOCRINO /ENDOCRINE SYSTEM

• Endocannabinoids in endocrine and related tumours (PubMed)

• A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells (PubMed)

​

​

VESCICA, VIE URINARIE, APPARATO GENITALE / BLADDER, GENITAL

• TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer (PubMed)

​

​

DOLORE / PAIN

• Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain (PubMed)

• Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial (PubMed)

• Marijuana extract helps prevent chemo pain (UPI)

• Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain (PubMed)

• Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain (PubMed)

• Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine (PubMed)

• Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial (PubMed)

• Cannabinoids for neuropathic pain (PubMed)

• Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue (PubMed)

• Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial (PubMed)

• The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain (PubMed)

• Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation (PubMed)

• Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy (PubMed)

• Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: Mechanisms involved (PubMed)

• Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action (PubMed)

• Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors (PubMed)

• Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes (PubMed)

• Cannabinoids in the management of difficult to treat pain (PubMed)

• Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain (PubMed)

• Marijuana extract helps prevent chemo pain (UPI)

• Pot users less likely to take painkillers (American News Report)

​

​

SLA - SCLEROSI MULTIPLA / MULTIPLE SCLEROSIS AND EPILEPSY

​

• Sativex for the management of multiple sclerosis symptoms (PubMed)

•  THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (PubMed)

• Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (PubMed)

• Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors (PubMed)

• Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial (PubMed)

• Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis (PubMed)

• Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis (PubMed)

• A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis (PubMed)

• Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain (PubMed)

• Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain (PubMed)

• Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials (PubMed)

• Medical Cannabis Helps ALS Patient Outlive her Own Doctor (Jahan Marcu)

 

​

INFIAMMAZIONI / INFLAMMATIONS

​

• Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (PubMed)

• The endocannabinoid system: an emerging key player in inflammation (PubMed)

• Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice (PubMed)

• Cannabinoids, endocannabinoids, and related analogs in inflammation (PubMed)

• Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor (PubMed)

• Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors (PubMed)

• Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis(PubMed)

• Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation(PubMed)

• Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement (PubMed)

• Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption (PubMed)

• Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation (PubMed)

• Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death (PubMed)

• Cannabinoids in clinical practice (PubMed)

​

​

PSICOPATOLOGIE E DIPENDENZE / PSIYCHOPATHOLOGIES AND ADDICTIONS

Dipendenze/ADDICTIONS

​

• Cannabidiol reduces cigarette consumption in tobacco smokers (PubMed)

• Inhibition of monoacylglycerol lipase enzyme reduces nicotine withdrawal (PubMed)

• Cannabidiol inhibits the reward-facilitating effect of morphine (PubMed)

• Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances (PubMed)

• Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats (PubMed)

• Impact of Cannabis Use during Stabilization on Methadone Maintenance Treatment(PubMed)

• Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010 (PubMed)

• Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents (PubMed)

• Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity (PubMed)

• Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder (ScienceDirect)

• Cannabidiol for the treatment of cannabis withdrawal syndrome (PubMed)

• Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: a national study  (PubMed)

​

​

Disturbi bipolari/BIPOLAR DISORDERS

​

• Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential (PubMed)

• Cannabidiol was ineffective for manic episode of bipolar affective disorder (PubMed)

​

​

Depressione/DEPRESSION

​

• Endocannabinoid system dysfunction in mood and related disorders (PubMed)

• Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa (PubMed)

• The endocannabinoid system and the treatment of mood and anxiety disorders (PubMed)

• Endocannabinoid signaling in the etiology and treatment of major depressive illness(PubMed)

• Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors (PubMed)

• Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants (PubMed)

• Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa (PubMed)

• Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress (PubMed)

• Serum contents of endocannabinoids are correlated with blood pressure in depressed women (PubMed)

• The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants (PubMed)

• Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures (PubMed)

​

​

Disturbi dell'umore/MOOD DISORDERS

​

• Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders (PubMed)

• The endocannabinoid system and the treatment of mood and anxiety disorders (PubMed)

• The endocannabinoid system and psychiatric disorders (PubMed)

• The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives (PubMed)

• Endocannabinoid system dysfunction in mood and related disorders (PubMed)

• Effects of cannabidiol (CBD) on regional cerebral blood flow (PubMed)

​

​

Schizofrenia/SCHYZOPRHENY

​

• Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug (PubMed)

• Cannabidiol as a potential treatment for psychosis (PubMed)

• Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (PubMed)

• Medical use of cannabis. Cannabidiol: A new light for schizophrenia? (PubMed)

• A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation (PubMed)

• Peripheral endocannabinoid system dysregulation in first-episode psychosis (PubMed)

• Cannabinoids and schizophrenia: Therapeutic prospects (PubMed)

• Antipsychotic-like effects of cannabidiol and rimonabant: Systematic review of animal and human studies (PubMed)

• Cannabidiol monotherapy for treatment-resistant schizophrenia (PubMed)

• Cannabis with high cannabidiol content is associated with fewer psychotic experiences(PubMed)

• Marijuana compound treats schizophrenia with few side effects: Clinical trial (Time)

• Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia?(PubMed)

​

​

Disordini ossessivi-compulsivi/OBSESSIVE-COMPULSIVE DISORDERS

​

• Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour(PubMed)

 

 

DIABETE / DIABETES

​

• The impact of marijuana use on glucose, insulin, and insulin resistance among US adults(American Journal of Medicine)

• Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy (PubMed)

• Cannabidiol lowers incidence of diabetes in non-obese diabetic mice (PubMed)

• Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes (PubMed)

• Cannabidiol arrests onset of autoimmune diabetes in NOD mice (PubMed)

• Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation(PubMed)

• Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes(PubMed)

• The endocannabinoid system in obesity and type 2 diabetes (PubMed)

• Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes(PubMed)

• The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications (PubMed)

• Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain (PubMed)

• Biochemical and immunohistochemical changes in delta-9-tetrahydrocannabinol-treated type 2 diabetic rats (PubMed)

• The impact of marijuana use on glucose, insulin, and insulin resistance among US adults(American Journal of Medicine)

• The potential use of cannabidiol in the therapy of metabolic syndrome (PubMed)

• Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes(PubMed)

 

 

FIBROMIALGIA / FIBROMYALGIA

​

• Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (PubMed)

• Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life (PubMed)

​

 

MORBO DI HUNTINGTON / HUNTINGTON'S DISEASE

​

• Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease (PubMed)

• Cannabinoids: Novel medicines for the treatment of Huntington’s disease (PubMed)

• Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB(1) and CB(2) receptors(PubMed)

• Controlled clinical trial of cannabidiol in Huntington’s disease (PubMed)

• Prospects for cannabinoid therapies in basal ganglia disorders (PubMed)

• Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice (PubMed)

 

 

ARTRITE / ARTHRITIS

​

• Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis (PubMed)

• The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis (PubMed)

• Involvment of the endocannabinoidi system in osteoarthritis pain(PubMed)

• The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55 (PubMed)

• Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (PubMed)

 

 

ARTEROSCLEROSI / ARTHEROSCLEROSIS

​

• The role of the endocannabinoid system in atherosclerosis (PubMed)

• Cannabinoid receptors in atherosclerosis (PubMed)

• The potential use of cannabidiol in the therapy of metabolic syndrome (PubMed)

 

​

COLITE E MORBO DI CROHN / COLITIS AND CROHN'S DISEASE

​

• Cannabidiol in inflammatory bowel diseases: a brief overview (PubMed)

• Cannabis finds its way into treatment of Crohn’s disease (PubMed)

• Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis(PubMed)

• Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis (PubMed)

• The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis (PubMed)

• Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice(PubMed)

• Cannabinoids and the gut: New developments and emerging concepts (PubMed)

• Endocannabinoids and the gastrointestinal tract (PubMed)

• Cannabinoids and gastrointestinal motility: Animal and human studies (PubMed)

• Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis (O’Shaughnessy’s)

• Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (PubMed)

• Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation (PubMed)

• Therapeutic potential of cannabinoid-based drugs (PubMed)

• Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology) (PubMed)

 

​

IPERATTIVITÀ E DISORDINI DELL'ATTENZIONE / HYPERACTIVITY AND ATTENTION DISORDERS

​

• Searching for a Neurobiological Basis for Self-Medication Theory in ADHD Comorbid With Substance Use Disorders (Pub Med)

• Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats (PubMed)

• Subtypes of Attention Deficit — Hyperactivity Disorder (ADHD) and cannabis use (PubMed)

• Childhood and current ADHD symptom dimensions are associated with more severe cannabis outcomes in college students (PubMed)

• Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report (PubMed)

• Fitness to drive in spite (because) of THC (PubMed)

 

​

DERMATOLOGIA / DERMATOLOGY

​

• Cannabidiol as a Treatment for Acne? (O’Shaughnessy’s)

• Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes (PubMed)

• The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities (PubMed)

• Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling (PubMed)

• Endocannabinoid signaling and epidermal differentiation (PubMed)

• Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis (PubMed)

• Epigenetic control of skin differentiation genes by phytocannabinoids (PubMed)

• A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ (PubMed)

• Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1 (PubMed)

• Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation (PubMed)

• Attenuation of allergic contact dermatitis through the endocannabinoid system (PubMed)

• Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus (PubMed)

 

​

AUTISMO / AUTISM

 

• Mutations found in individuals with autism interfere with endocannabinoid signaling in the brain (Science Daily)

• Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders (PubMed)

• A novel approach to the symptomatic treatment of autism (Lester Grinspoon M.D., O’Shaughnessy’s)

• Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders (PubMed)

• Targeting the endocannabinoid system in the treatment of fragile X syndrome (PubMed)

 

​

MORBO DI ALZHEIMER / ALZHEIMER'S DISEASE

​

• The therapeutic potential of the endocannabinoid system for Alzheimer’s disease (PubMed)

• Endocannabinoid signalling in Alzheimer’s disease (PubMed)

• A molecular link between the active component of marijuana and Alzheimer’s disease pathology (PubMed)

• Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells (PubMed)

• The Potential Therapeutic Effects of THC on Alzheimer’s Disease (PubMed)

• The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease (PubMed)

• Cannabinoids for the treatment of dementia (PubMed)

• Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression (PubMed)

• Cannabidiol: A promising drug for neurodegenerative disorders? (PubMed)

• Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition (PubMed)

• The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses(PubMed)

• The role of phytochemicals in the treatment and prevention of dementia (PubMed)

• Cannabinoids for the treatment of dementia (PubMed)

• Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement (PubMed)

• Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic (Pub Med)

• Can Marijuana Prevent Alzheimer’s? (Next Avenue)

​

​

AIDS

• Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpes virus-infected endothelium (PubMed)

​

​

ANORESSIA E DISTURBI DELL'APPETITO / ANOREXIA

​

• Leptin, ghrelin, and endocannabinoids: Potential therapeutic targets in anorexia nervosa(PubMed)

• The role of the endocannabinoid system in eating disorders: Neurochemical and behavioural preclinical evidence (PubMed)

• Cancer cachexia and cannabinoids (PubMed)

​

​

ANSIA E DISTURBI DEL SONNO / ANXIETY AND SLEEP DISORDERS

​

• Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug (PubMed)

• Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa (PubMed)

• Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients (PubMed)

• Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder (PubMed)

• Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation (PubMed)

• Effects of cannabidiol (CBD) on regional cerebral blood flow (PubMed)

• The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors (PubMed)

• The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system (PubMed)

• Plant-based medicines for anxiety disorders, part 2: A review of clinical studies with supporting preclinical evidence (PubMed)

​

​

Disturbi del sonno/SLEEP DISORDERS

​

• The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent (PubMed)

• Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine (PubMed)

• Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats(PubMed)

• Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults (PubMed)

• Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats (PubMed)

• Endocannabinoid modulation of cortical up-states and NREM sleep (PubMed)

• Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat (PubMed)

​

​

ASMA / ASTHMA

​

• The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke (PubMed)

• Allergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma (PubMed)

• Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs (PubMed)

• Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways (PubMed)

• Bronchodilator effect of delta1-tetrahydrocannabinol (PubMed)

​

​

CONDIZIONI DI STRESS / STRESS

​

• Endogenous cannabinoid signaling is essential for stress adaptation (PubMed)

• Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders (PubMed)

• Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output (PubMed)

• Neuromodulators, stress and plasticity: a role for endocannabinoid signalling (PubMed)

• Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress (PubMed)

• Endocannabinoids and stress (PubMed)

• Stress regulates endocannabinoid-CB1 receptor signaling (PubMed)

• Chronic Stress Impairs α1-Adrenoceptor-Induced Endocannabinoid-Dependent Synaptic Plasticity in the Dorsal Raphe Nucleus (Pub Med)

• Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance (PubMed)

• Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression (PubMed)

• Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory (PubMed)

• The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system (PubMed)

• Low-frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid (PubMed)

• Motion sickness, stress and the endocannabinoid system (PubMed)

• Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system (PubMed)

​

​

PATOLOGIE ENDOCRINE / ENDOCRINE DISORDERS

​

• Endocannabinoid system participates in neuroendocrine control of homeostasis (PubMed)

• The emerging role of the endocannabinoid system in endocrine regulation and energy balance (PubMed)

• Endocannabinoids in endocrine and related tumours (PubMed)

• Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas (PubMed)

• The role of the endocannabinoid system in the neuroendocrine regulation of energy balance (PubMed)

​

​

GLAUCOMA

​

• Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite (PubMed)

• Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study(PubMed)

​

​

PATOLOGIE CARDIOVASCOLARI / CARDIOVASCULAR DISEASES

​

• Cannabidiol limits Tcell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation.

• Is the cardiovascular system a therapeutic target for cannabidiol?

• Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion

• Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy

• The Effect of Cannabidiol on Ischemia/Reperfusion-Induced Ventricular Arrhythmias: The Role of Adenosine A1 Receptors

• Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury

• Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension

• Oleamide: A fatty acid amide signaling molecule in the cardiovascular system?

 

​

PATOLOGIE DEL FEGATO / LIVER DISEASES

​

• The endocannabinoid system and liver diseases (PubMed)

• Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death (PubMed)

• Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis (PubMed)

• Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats(PubMed)

• Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol (PubMed)

• Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice (PubMed)

• Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation(PubMed)

 

​

CEFALEE / HEADACHE

​

• Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (PubMed)

• Effects of anandamide in migraine: data from an animal model (PubMed)

• Cannabinoids and hallucinogens for headache (PubMed)

• The endocannabinoid system and migraine (PubMed)

• Variations in the cannabinoid receptor 1 gene predispose to migraine (PubMed)

• Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache

 

​

NAUSEA

​

• Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system(PubMed)

• Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus (PubMed)

• Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation (PubMed)

• Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews(PubMed)

• Regulation of nausea and vomiting by cannabinoids (PubMed)

• Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats (PubMed)

• Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting (PubMed)

 

 

CONDIZIONI NEURODEGENERATIVE / NEURODEGENERATIVE CONDITIONS

​

• Cannabidiol: A promising drug for neurodegenerative disorders? (PubMed)

• Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? (PubMed)

• Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder (PubMed)

• Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders (PubMed)

• Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection (Pub Med)

 

​

OSTEOPOROSI / OSTHEOPOROSIS

​

• Cannabinoid receptors as target for treatment of osteoporosis: A tale of two therapies(PubMed)

• Cannabinoids and bone: Friend or foe? (PubMed)

• Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells (PubMed)

• Cannabinoids and the skeleton: From marijuana to reversal of bone loss (PubMed)

• The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy (PubMed)

• The endovanilloid/endocannabinoid system in human osteoclasts: Possible involvement in bone formation and resorption (PubMed)

• Endocannabinoids and the regulation of bone metabolism (PubMed)

• Cannabinoid receptors and the regulation of bone mass (PubMed)

• Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health (PubMed)

• Peripheral cannabinoid receptor, CB2, regulates bone mass (PubMed)

• Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors(PubMed)

• Long-chain polyunsaturated fatty acids may mutually benefit both obesity and osteoporosis (PubMed)

• Skeletal lipidomics: Regulation of bone metabolism by fatty acid amide family (PubMed)

​

​

MORBO DI PARKINSON / PARKINSON'S DISEASE

​

• Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial (PubMed)

• Prospects for cannabinoid therapies in basal ganglia disorders (PubMed)

• Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant and cannabinoid receptor-independent properties(PubMed)

• Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease (PubMed)

• Cannabidiol for the treatment of psychosis in Parkinson’s disease (PubMed)

• Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease (PubMed)

• Therapeutic potential of cannabinoids in CNS disease (PubMed)

• Cannabidiol can improve complex sleep-related behaviours associated with rapid eyemovement sleep behaviour disorder in Parkinson’s disease patients: a case series (PubMed)

​

​

DISORDINI POST-TRAUMATICI / POST-TRAUMATIC DISORDERS

​

• The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD (PubMed)

• Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks (PubMed)

• Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear(PubMed)

• Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via CannabinoidReceptors (PubMed)

• Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors (PubMed)

• Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis (PubMed)

• Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence (PubMed)

• Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment (PubMed)

• The endocannabinoid system and extinction learning (PubMed)

• A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers (PubMed)

• Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit (PubMed)

• Non-antidepressant long-term treatment in post-traumatic stress disorder (PubMed)

• The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system (PubMed)

• Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid Receptors (PubMed)

​

​

ANEMIA FALCIFORME / SICKLE CELL ANEMIA

​

• Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: Modulation by cannabinoids (Pub Med)

• Cannabis use in sickle cell disease: A questionnaire study (Pub Med)

​

​

ICTUS/STROKE

​

• Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury (PubMed)

• Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism(PubMed)

• Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism (PubMed)

• Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function (PubMed)

• Protective Effects of Cannabidiol Against Hippocampal Cell Death and Cognitive Impairment Induced by Bilateral Common Carotid Artery Occlusion in Mice (PubMed)

• Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance (PubMed)

​

​